Dustin Fowler
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $8,889 of the $10,032 with a category attached, or 88.6%. It is spread thinly across 38 manufacturers, the largest accounting for just 17.0% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,464, 2.2 times the $1,109 reported in 2019.
Across 392 payments — averaging $25.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Sanofi$1K
- GSK$1K
- Regeneron Healthcare Solutions, Inc.$967
- Pfizer$757
- Novartis$412
- plus $4K from 32 others
Across 41 payments — averaging $798.01 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$26K
- AstraZeneca$7K
What the payments were for
- Speaking & faculty fees$1752%
- Grants$7007%
- Food & beverage$8,88989%
- Education$2673%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 50 | $1,709 |
| Sanofi | 27 | $1,403 |
| GSK | 75 | $1,246 |
| Regeneron Healthcare Solutions, Inc. | 42 | $967 |
| Pfizer | 45 | $757 |
| Novartis | 21 | $412 |
| Blueprint Medicines Corporation | 14 | $328 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $326 |
| Amgen | 17 | $318 |
| CSL Behring | 11 | $314 |
| Jubilant Hollisterstier LLC | 1 | $261 |
| Aimmune Therapeutics, Inc. | 2 | $199 |
| LEO Pharma Inc. | 3 | $168 |
| Genentech USA, Inc. | 2 | $161 |
| Kaleo, Inc. | 11 | $155 |
| Sanofi-aventis U.S. LLC | 2 | $127 |
| Pharming Healthcare, Inc. | 5 | $120 |
| Alk-abello, Inc | 5 | $118 |
| Mylan Specialty L.p. | 6 | $116 |
| Grifols USA, LLC | 4 | $94 |
| ARS Pharmaceuticals Operations, Inc. | 5 | $93 |
| Lilly USA, LLC | 3 | $75 |
| Octapharma USA, Inc. | 2 | $71 |
| Incyte Corporation | 3 | $64 |
| Viatris Specialty LLC | 2 | $56 |
| Regeneron | 2 | $55 |
| Hospira, Inc. | 3 | $53 |
| Merck | 3 | $50 |
| Shire North American Group Inc | 2 | $44 |
| Ionis Pharmaceuticals, Inc. | 1 | $36 |
| Novo Nordisk | 2 | $32 |
| AbbVie | 1 | $23 |
| Teva Pharmaceuticals USA, Inc. | 1 | $18 |
| Phadia US Inc. | 1 | $14 |
| Phathom Pharmaceuticals, Inc. | 2 | $14 |
| Hikma Pharmaceuticals USA | 1 | $13 |
| USWM, LLC | 1 | $12 |
| Organon | 1 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,032 in reported general payments places this provider in the 75th percentile of 69 allergy providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 13 | $143,807 |
| Dupixent SyringeDupilumab | 19 | $75,555 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 80 | $56,252 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 38 | $33,003 |
| Breo ElliptaFluticasone/Vilanterol | 44 | $17,788 |
| Spiriva RespimatTiotropium Bromide | 22 | $12,115 |
| Epinephrine | 12 | $2,656 |
| Ipratropium Bromide | 92 | $2,419 |
| Azelastine Hcl | 57 | $1,194 |
| Montelukast Sodium | 139 | $1,191 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 33 | $981 |
| Fluticasone Propionate | 64 | $899 |
| Doxycycline Monohydrate | 20 | $173 |
| Azithromycin | 22 | $72 |
| Prednisone | 44 | $48 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| CSL BehringPrivigen | $314 | $143,80713 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $1,246 | $74,041124 claims |
| AstraZenecaBreztri Aerosphere | $1,709 | $33,00338 claims |
| Hikma Pharmaceuticals USAEpinephrine | $13 | $2,65612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 69 allergy providers in Texas.
Other allergy in Waco
- Gary GrossDallas$602K
- Rene LeonSouthlake$48K
- Christina HuddlestonDallas$26K
- Alireza ShakouriSouthlake$17K
- Zachary MarshallRoanoke$17K
- Stuart AbramsonSan Angelo$16K
- Patricia DingerSan Antonio$15K
- Brian MillerGeorgetown$15K
- Carlos VitalHouston$14K
- David FuentesBoerne$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.